AUTHOR=Sajjadi Elham , Venetis Konstantinos , Ivanova Mariia , Noale Marianna , Blundo Concetta , Di Loreto Eugenia , Scarfone Giovanna , Ferrero Stefano , Maggi Stefania , Veronesi Paolo , Galimberti Viviana E. , Viale Giuseppe , Peccatori Fedro A. , Fusco Nicola , Guerini-Rocco Elena 

TITLE=Immune microenvironment dynamics in breast cancer during pregnancy: impact of gestational age on tumor-infiltrating lymphocytes and prognosis

JOURNAL=Frontiers in Oncology

VOLUME=13

YEAR=2023

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1116569

DOI=10.3389/fonc.2023.1116569

ISSN=2234-943X

ABSTRACT=<sec><title>Background</title><p>Breast cancer during pregnancy (PrBC) is a rare condition known for its aggressive clinical behavior. The presence of tumor-infiltrating lymphocytes (TILs) has been shown to have a significant impact on the prognosis of these patients. Despite some biological characteristics of the tumor that may differ depending on the gestational age, little is known about the dynamics of the immune landscape within the tumor microenvironment (TME) in PrBC. Therefore, in this study, our objective was to gain comprehensive insights into the relationship between gestational age at breast cancer diagnosis and the composition of the TME.</p></sec><sec><title>Methods</title><p><italic>n</italic> = 108 PrBC were selected from our institutional registry and categorized based on the gestational age by trimester. For all cases, TILs were profiled according to the International TILs Working Group recommendations, and subtyped by CD4, CD8, and forkhead box P3 (FOXP3) immunohistochemistry. PD-L1 was tested according to the combined positive score (CPS) using the IHC 22C3 pharmDx assay, with a cutoff value of ≥10 for positivity. The statistical approach encompassed Fisher’s and Chi-squared tests, with appropriate adjustments for multiple comparisons, logistic regression models, and survival analyses based on the Kaplan–Meier method.</p></sec><sec><title>Results</title><p>The proportion of patients with poorly differentiated (G3) neoplasms increased as the gestational age advanced (first trimester, <italic>n</italic> = 25, 56.8%; second trimester, <italic>n</italic> = 27, 69.2%; third trimester, <italic>n</italic> = 21, 87.5%; <italic>p</italic> = 0.03). The histologic subtypes as well as the hormone receptor (HR) and HER2 status did not show significant changes across different pregnancy trimesters. In the HR+/HER2– subtype, there was a higher proportion of tumors with high/moderate TILs in the early phases of pregnancy, similar to FOXP3 expression (TILs: first trimester, <italic>n</italic> = 10, 35.7%; second trimester, <italic>n</italic> = 2, 10.5%; third trimester, <italic>n</italic> = 0; <italic>p</italic> = 0.02; FOXP3: first trimester, <italic>n</italic> = 10, 40%; second trimester, <italic>n</italic> = 3, 15.8%; third trimester, <italic>n</italic> = 0; <italic>p</italic> = 0.03). The median follow-up for our cohort was 81 months. Patients who relapsed after a breast cancer diagnosis during the first trimester were more frequently PD-L1-negative, unlike those with no disease recurrence (<italic>n</italic> = 9, 100% vs. <italic>n</italic> = 9, 56.3%; <italic>p</italic> = 0.03; hormone therapy and <italic>n</italic> = 9, 100% vs. <italic>n</italic> = 7, 53.9%; <italic>p</italic> = 0.02; chemotherapy). No statistically significant differences were seen among the three trimesters in terms of survival outcome.</p></sec><sec><title>Conclusion</title><p>The TME dynamics of HR+/HER2− PrBC vary based on gestational age, suggesting that immune tolerance expression during later gestational age could explain the increased aggressiveness of tumors diagnosed at that stage.</p></sec>